Price movement over the last 24 hours
ADMA Biologics Inc vs Advanced Drainage Systems Inc — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while Advanced Drainage Systems Inc trades at $144.14 (market cap $11.42B). The key difference: Advanced Drainage Systems Inc is far larger — about 5.4× ADMA Biologics Inc's market cap, and Advanced Drainage Systems Inc pays a 0.54% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | WMS | |
|---|---|---|
Market Cap | $2.13B | $11.42B |
Sector | Health | Industrials |
52-Week High | $20.38 | $175.38 |
52-Week Low | $7.60 | $110.89 |
Enterprise Value | $2.20B | $12.99B |
Dividend Yield | — | 0.54% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Advanced Drainage Systems (WMS) trades at $149.07, down 2.04% over 24 hours. The stock shows strong profitability with a 13.98% net income margin and consistent earnings beats in recent quarters. Technical indicators are bullish overall, with moving averages supporting an uptrend. Recent news includes a dividend increase and mixed analyst sentiment, with a consensus price target of $183.00. Cash flow trends indicate robust operational performance despite a recent dip in net cash flow.
Outlook remains positive due to solid fundamentals and growth in stormwater management demand. Risks include competitive pressures and potential margin compression. The stock presents a moderate buy opportunity with upside to analyst targets, balanced by near-term volatility and sector-specific headwinds.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →